ARTICLE | Deals
As mRNA vaccines gain traction, GSK-CureVac deal aims to advance the modality for future pandemics
July 21, 2020 2:09 AM UTC
As several COVID-19 vaccine front-runners move ahead with mRNA-based programs, CureVac and GSK are looking ahead to apply the modality to future pandemics.
GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) will invest £130 million ($163.5 million) for a stake of about 10% in the biotech, a month after the German government secured a 23% claim (see “Germany Takes Stake in CureVac”)...